Why is Neil Woodford so bullish on drugmakers GlaxoSmithKline plc, AstraZeneca plc and 4D Pharma plc?

Will GlaxoSmithKline plc (LON: GSK), AstraZeneca plc (LON: AZN) and 4D Pharma plc (LON: DDDD) be the cure for poor returns?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford’s Equity Income Fund is heavily weighted towards healthcare companies, and GlaxoSmithKline (LSE: GSK) makes up 6.3% of this entire fund. Woodford hasn’t only been buying the company for its 5%-plus dividend though, but also sees great value in the company being broken up. This is a common refrain among fund managers as GSK CEO Sir Andrew Witty has bucked the recent consensus amongst pharma giants and charted a path towards more reliance on consumer healthcare goods such as toothpaste and over-the-counter flu treatments.

These consumer-facing goods now bring in nearly 30% of GSK’s revenue, but their 17% operating margins significantly lag the 32% brought in by pharmaceuticals or 29% from vaccines. While 17% margins are nothing to sneer at, they do bring down group performance, which is especially galling for some investors as GSK’s new HIV drugs finally enter the market and bring in significant revenue. However, Witty’s turnaround is beginning to bear fruit as earnings are expected to increase at a low-double-digits clip this year and will once again cover solid dividends.

Changing business model

AstraZeneca (LSE: AZN) is another major holding in Woodford’s income fund thanks to the company’s 4.7% yielding dividend. AstraZeneca, like many of its American counterparts, has doubled down on high-risk-but-high-profit speciality drugs. CEO Pascal Soriot sees the company’s future in designing targeted cancer treatments for a smaller subset of the population. This requires a smaller sales force than the company currently boasts, which will bring down operating costs but also require higher R&D spending.

This shift in business model comes as the company lost its US patents to Nexium in 2014 and will lose Crestor patents this year, which management is expecting to bring earnings down in the mid-single-digits. These two drugs combined brought in roughly a third of revenue in prior years, so generic competition will impact the bottom line for several years to come. Despite this, the growth areas now bring in 56% of revenue and the company has a well-stocked pipeline after spending over $6.2bn on acquisitions in the past two years alone. Looking forward, the company’s long-term focus on high margin oncology treatments makes good sense and the company has an enviable pipeline of new drugs to tide it over in the short term as earnings fall due to generic competition.

A risk too far

With no revenue whatsoever, small cap 4D Pharma (LSE: DDDD) is a far cry from GSK or AstraZeneca, yet Woodford owns nearly 24% of the company’s outstanding shares. 4D is a major bet on the viability of using beneficial bacteria to treat diseases ranging from asthma to multiple sclerosis. So far, the company has acquired a bevy of small drugs developers and now has 15 drugs in development with two currently in patient trials and three more expected to begin them this year.

After two share placements, the company had £85.4m in cash at year-end, which should fund operations and acquisitions for several years to come. 4D is one to watch then, but the risks of investing in a company with no revenue that relies on issuing shares to fund development is too risky a prospect for me until results from more clinical trials are released.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »